Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) EPS (Basic) (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed EPS (Basic) for 9 consecutive years, with -$0.73 as the latest value for Q4 2025.

  • Quarterly EPS (Basic) fell 7.35% to -$0.73 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.97 through Dec 2025, down 15.12% year-over-year, with the annual reading at -$2.97 for FY2025, 15.56% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.73 at Denali Therapeutics, up from -$0.74 in the prior quarter.
  • The five-year high for EPS (Basic) was $1.34 in Q2 2023, with the low at -$0.87 in Q4 2023.
  • Average EPS (Basic) over 5 years is -$0.58, with a median of -$0.68 recorded in 2021.
  • The sharpest move saw EPS (Basic) skyrocketed 379.17% in 2023, then plummeted 144.03% in 2024.
  • Over 5 years, EPS (Basic) stood at -$0.62 in 2021, then dropped by 20.97% to -$0.75 in 2022, then dropped by 16.0% to -$0.87 in 2023, then grew by 21.84% to -$0.68 in 2024, then dropped by 7.35% to -$0.73 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.73, -$0.74, and -$0.72 for Q4 2025, Q3 2025, and Q2 2025 respectively.